Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Insider Terrie Curran Sells 19,109 Shares

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) insider Terrie Curran sold 19,109 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $6.59, for a total transaction of $125,928.31. Following the sale, the insider now owns 360,465 shares of the company’s stock, valued at approximately $2,375,464.35. This represents a 5.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Phathom Pharmaceuticals Stock Performance

Shares of Phathom Pharmaceuticals stock opened at $6.90 on Friday. The stock has a market cap of $471.80 million, a P/E ratio of -1.21 and a beta of 0.56. The stock’s fifty day moving average is $8.00 and its 200 day moving average is $12.47. Phathom Pharmaceuticals, Inc. has a one year low of $6.07 and a one year high of $19.71.

Phathom Pharmaceuticals (NASDAQ:PHAT) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($1.32) EPS for the quarter, topping the consensus estimate of ($1.57) by $0.25. The company had revenue of $16.35 million during the quarter, compared to the consensus estimate of $12.54 million. During the same period last year, the business earned ($0.76) EPS. Analysts predict that Phathom Pharmaceuticals, Inc. will post -4.74 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently commented on PHAT. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Phathom Pharmaceuticals in a report on Friday, January 10th. HC Wainwright restated a “buy” rating and set a $28.00 price target on shares of Phathom Pharmaceuticals in a research note on Thursday, December 12th.

Institutional Investors Weigh In On Phathom Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PHAT. Jennison Associates LLC increased its stake in shares of Phathom Pharmaceuticals by 112.7% in the third quarter. Jennison Associates LLC now owns 5,866,389 shares of the company’s stock worth $106,064,000 after purchasing an additional 3,108,810 shares in the last quarter. FMR LLC increased its stake in Phathom Pharmaceuticals by 49,000.7% in the 3rd quarter. FMR LLC now owns 1,304,114 shares of the company’s stock worth $23,578,000 after buying an additional 1,301,458 shares in the last quarter. Checkpoint Capital L.P. raised its holdings in Phathom Pharmaceuticals by 71.9% during the third quarter. Checkpoint Capital L.P. now owns 1,504,307 shares of the company’s stock valued at $27,198,000 after acquiring an additional 629,307 shares during the period. Portolan Capital Management LLC raised its holdings in Phathom Pharmaceuticals by 50.4% during the third quarter. Portolan Capital Management LLC now owns 1,699,918 shares of the company’s stock valued at $30,735,000 after acquiring an additional 569,829 shares during the period. Finally, Point72 Asset Management L.P. bought a new position in shares of Phathom Pharmaceuticals in the third quarter worth about $7,952,000. Institutional investors own 99.01% of the company’s stock.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.